SGMO Stock - Sangamo Therapeutics, Inc.
Unlock GoAI Insights for SGMO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M |
| Gross Profit | $57.80M | $176.23M | $99.19M | $110.70M | $-62,455,000 |
| Gross Margin | 100.0% | 100.0% | 89.1% | 100.0% | -52.8% |
| Operating Income | $-103,969,000 | $-274,005,000 | $-201,281,000 | $-183,337,000 | $-129,551,999 |
| Net Income | $-97,941,000 | $-257,831,000 | $-192,278,000 | $-178,286,000 | $-120,996,000 |
| Net Margin | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% |
| EPS | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 |
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 7th 2025 | Barclays | Downgrade | Equal Weight | $1 |
| December 13th 2024 | Truist | Upgrade | Buy | $7 |
| December 10th 2024 | H.C. Wainwright | Reiterated | Buy | $10 |
| November 3rd 2023 | RBC Capital Mkts | Downgrade | Sector Perform | $2← $6 |
| April 28th 2023 | BofA Securities | Downgrade | Underperform | $1.5← $5 |
| February 27th 2023 | Wedbush | Upgrade | Outperform | $16 |
| January 6th 2023 | BofA Securities | Downgrade | Neutral | $5← $8 |
| June 13th 2022 | Wedbush | Resumed | Neutral | $5 |
Earnings History & Surprises
SGMOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $0.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.03 | $-0.11 | -266.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q1 2025 | Mar 17, 2025 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $0.01 | $0.04 | +237.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.16 | $-0.17 | -6.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.25 | $-0.34 | -36.0% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.33 | $0.12 | +136.4% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.35 | $-0.34 | +2.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.35 | $-0.29 | +17.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.34 | $-0.26 | +23.5% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.34 | $-0.33 | +2.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.30 | $-0.33 | -10.0% | ✗ MISS |
Latest News
Sangamo Therapeutics Initiates Rolling Submission Of BLA To FDA Seeking Accelerated Approval Of Isaralgagene Civaparvovec, Or ST-920, Investigational Gene Therapy For Treatment Of Adults With Fabry Disease
📈 PositiveSangamo rises as FDA grants Fast Track status to neuropathic pain asset
📈 PositiveSangam Therapeutics shares are trading higher after the FDA granted Fast Track Designation to ST-503.
📈 PositiveSangamo Therapeutics Receives FDA Fast Track Designation For ST-503 In Treatment Of Small Fiber Neuropathy
📈 PositiveSangamo rises as FDA accepts rolling submission request for gene therapy
📈 PositiveSangamo Therapeutics shares are trading higher after the company announced that the FDA accepted its request for a rolling submission and review of the Biologics License Application for isaralgagene civaparvovec
📈 PositiveSangamo Therapeutics Biologics License Application Gets FDA's Acceptance For Isaralgagene Civaparvovec To Treat Fabry Disease
📈 PositiveBarclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1
📉 NegativeSangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeSangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate
📉 NegativeOn September 9, Sangamo Therapeutics CFO Prathyusha Duraibabu Resigned
📉 NegativeHC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
📈 PositiveSangamo Therapeutics prices $23M securities offering
➖ NeutralFrequently Asked Questions about SGMO
What is SGMO's current stock price?
What is the analyst price target for SGMO?
What sector is Sangamo Therapeutics, Inc. in?
What is SGMO's market cap?
Does SGMO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SGMO for comparison